Promising Biotech Stocks To Research - July 12th

Thermo Fisher Scientific, AbbVie, Danaher, Veeva Systems, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Cencora are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use biological processes and cutting-edge technologies to develop new drugs, therapies, diagnostics or agricultural products. Because these firms require heavy investment in research and face lengthy regulatory approvals and binary clinical trial outcomes, their stock prices tend to be more volatile than those of established industries. Investors are attracted by the sector’s high-growth potential but must accept elevated risk and uncertainty. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

TMO traded up $4.29 during midday trading on Friday, hitting $435.02. 2,511,384 shares of the company were exchanged, compared to its average volume of 1,995,412. The firm has a market capitalization of $164.22 billion, a P/E ratio of 25.51, a P/E/G ratio of 2.29 and a beta of 0.77. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $627.88. The firm's 50 day moving average price is $409.39 and its 200-day moving average price is $476.59. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64.

Read Our Latest Research Report on TMO

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded down $2.68 during midday trading on Friday, reaching $192.32. The company's stock had a trading volume of 4,990,162 shares, compared to its average volume of 6,302,947. The firm has a market capitalization of $339.71 billion, a price-to-earnings ratio of 81.84, a PEG ratio of 1.29 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. The firm has a 50 day moving average price of $187.01 and a two-hundred day moving average price of $188.98. AbbVie has a fifty-two week low of $163.81 and a fifty-two week high of $218.66.

Read Our Latest Research Report on ABBV

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of NYSE:DHR traded down $0.71 during midday trading on Friday, reaching $204.80. The company's stock had a trading volume of 2,369,010 shares, compared to its average volume of 3,504,283. The firm has a market capitalization of $146.57 billion, a price-to-earnings ratio of 39.77, a PEG ratio of 2.89 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The firm has a 50 day moving average price of $196.05 and a two-hundred day moving average price of $206.47. Danaher has a fifty-two week low of $171.00 and a fifty-two week high of $281.70.

Read Our Latest Research Report on DHR

Veeva Systems (VEEV)

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

Shares of NYSE:VEEV traded down $5.82 during midday trading on Friday, reaching $275.82. The company's stock had a trading volume of 1,660,228 shares, compared to its average volume of 1,169,879. The firm has a market capitalization of $45.07 billion, a price-to-earnings ratio of 58.44, a PEG ratio of 2.23 and a beta of 0.98. The firm has a 50 day moving average price of $266.10 and a two-hundred day moving average price of $239.37. Veeva Systems has a fifty-two week low of $177.41 and a fifty-two week high of $291.69.

Read Our Latest Research Report on VEEV

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of NASDAQ:VRTX traded down $10.68 during midday trading on Friday, reaching $468.85. The company's stock had a trading volume of 892,738 shares, compared to its average volume of 1,424,305. The firm has a market capitalization of $120.40 billion, a price-to-earnings ratio of -119.60 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. The firm has a 50 day moving average price of $447.71 and a two-hundred day moving average price of $460.40. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Read Our Latest Research Report on VRTX

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Alnylam Pharmaceuticals stock traded down $7.70 during midday trading on Friday, reaching $314.94. The stock had a trading volume of 1,081,877 shares, compared to its average volume of 856,180. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $333.70. The company has a market capitalization of $41.07 billion, a P/E ratio of -150.69 and a beta of 0.23. The company has a fifty day moving average price of $301.17 and a two-hundred day moving average price of $268.77. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88.

Read Our Latest Research Report on ALNY

Cencora (COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Cencora stock traded down $2.25 during midday trading on Friday, reaching $295.07. The stock had a trading volume of 970,795 shares, compared to its average volume of 1,509,975. Cencora has a 12 month low of $218.65 and a 12 month high of $309.35. The company has a market capitalization of $57.19 billion, a P/E ratio of 34.23, a PEG ratio of 1.47 and a beta of 0.57. The company has a fifty day moving average price of $291.91 and a two-hundred day moving average price of $269.69. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01.

Read Our Latest Research Report on COR

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.